Loading
Emergent BioSolutions Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 15 May 2025.
Emergent BioSolutions Inc.: what insiders have been doing
This page follows insider dealings at Emergent BioSolutions Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Gaithersburg, United States. The group dates from 1998. 13 insiders have disclosed 38 filings since 18 October 2025.
Only sales appear on the open market, 6 sales in all totalling €469k, filed by 4 insiders. DeGolyer Donald W filed the largest sale, €163k, on 12 November 2025.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Across the 5,812 companies tracked on its exchange, the median is 19 filings; at 38 filings, this issuer sits above that mark. The full history, which starts in 2016, counts 2 purchases against 26 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 742.9 m USD and net income at 52.6 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
212
Thresholds
n/a
Buy Volume
€410,945
2 ops. · all time
Sell Volume
€2M
26 ops. · all time
Who traded when
BuySaleDonald W. DeGolyer4 sales
Paul Anthony Williams2 sales
Zoon Kathryn C2 sales
Coleen Glessner1 sale
Dayal Sujata Tyagi1 sale
Fowler Neal Franklin1 sale
+4 other insiders
Since the insiders bought
- +22.4%Entry US$6.64 · Close at T+365 US$8.13
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 3,167 of 24,148 companies
71.3
score / 100
Value96
Quality47
FCF yld44%
Earn yld15%
EV/EBITDA3.9x
ROE-40%
Gross mgn54%
Net mgn7.5%
Debt/EBITDA2.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$6.91
Analyst consensus
2 analysts2.00/5
US$10.00Target US$11.00(+59%)US$12.00
Income statement
RevenueUS$705.2M
Gross profitUS$379M54% margin
EBITDAUS$237.9M34% margin
Net incomeUS$52.6M-23.0% margin
Valuation
PER (forward)6.6x
P/Book1.0x
Beta2.29
Balance sheet & cash
Market capUS$354.3M
Total debtUS$572.1M
Free Cash FlowUS$156.8M
Debt / Equity172%
Profitability & ownership
ROE-40.3%
ROA6.9%
% insiders4.2%
% institutions90.5%
Last declaration on 7 October 2026
Declarations212 total
17,800 shares@ US$7.08540.035% mcap100.0% of flowCommonSEC144:0001950047-26-010097
17,800 shares@ US$7.090.035% mcap19.1% of flowCommon StockSEC:0001583098-26-000008:0
3,000 shares@ US$6.530.0060% mcap8.1% of flowCommon StockSEC:0001961994-26-000029:0
3,000 shares@ US$6.53050.0055% mcap43.8% of flowCommonSEC144:0001950047-26-009931
3,000 shares@ US$8.40180.0074% mcap100.0% of flowCommonSEC144:0001950047-26-006683
1,741 sharesCommon StockSEC:0001989644-26-000011:0
3,964 sharesCommon StockSEC:0001196632-26-000017:0
2,018 sharesCommon StockSEC:0001919170-26-000016:0
694 sharesCommon StockSEC:0001961994-26-000021:0
162,680 shares0Common StockSEC:0001196632-26-000013:0
187,708 shares0Common StockSEC:0001242215-26-000012:0
100,111 shares0Common StockSEC:0001919170-26-000012:0
100,111 shares0Common StockSEC:0001961994-26-000017:0
100,111 shares0Common StockSEC:0001989644-26-000007:0
104,282 shares0Common StockSEC:0002043716-26-000007:0
100,111 shares0Common StockSEC:0002044279-26-000007:0
4,000 shares@ US$8.440.014% mcap14.9% of flowCommon StockSEC:0001961994-26-000013:0
10,636 shares@ US$8.4469.1% of flowCommon StockSEC:0002044279-26-000003:0
6,465 shares@ US$8.4472.9% of flowCommon StockSEC:0002043716-26-000005:0
9,493 shares@ US$8.4437.6% of flowCommon StockSEC:0001989644-26-000005:0
9,397 shares@ US$8.4434.9% of flowCommon StockSEC:0001961994-26-000009:0
5,006 shares@ US$8.99100.0% of flowCommon StockSEC:0001190344-26-000010:0
8,199 shares@ US$8.447.7% of flowCommon StockSEC:0001919170-26-000009:0
37,055 shares@ US$8.4446.2% of flowCommon StockSEC:0001242215-26-000008:0
23,650 shares@ US$8.4419.0% of flowCommon StockSEC:0001196632-26-000009:0
25 of 212 declarations
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. (ticker EBS) is a U.S.-based life sciences company listed on the NYSE in the United States, with headquarters in Gaithersburg, Maryland. The company built its franchise around public health preparedness and response, with a long-standing focus on medical countermeasures and emergency-use products. Its corporate history is closely tied to BioThrax, the anthrax vaccine that helped establish Emergent’s identity and positioned it as a specialized supplier to government and public-sector customers. The company’s website notes that it began operations partnering with the U.S. government to supply BioThrax, and that its common stock trades on the New York Stock Exchange. ([emergentbiosolutions.com](https://www.emergentbiosolutions.com/our-company/?utm_source=openai))
According to Emergent’s 2025 annual report, the business is now organized around four core product and service categories: anthrax medical countermeasures, naloxone commercial products, smallpox medical countermeasures, and Emergent Bioservices CDMO services. Management describes the company as a global life sciences platform focused on innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring public health threats. It targets several threat areas, including CBRNE, emerging infectious diseases, emerging health crises, and acute, emergency and community care. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm?utm_source=openai))
Read moreShow less
From an equity analyst perspective, Emergent is a niche, high-barrier business rather than a broad-based pharmaceutical platform. Its competitive position rests on specialized manufacturing capabilities, regulatory know-how, and long-duration relationships with government agencies and commercial partners. That specialization creates strategic value in procurement-driven markets, where trust, compliance, and operational reliability matter as much as product innovation. At the same time, the model carries concentration risk, especially given the importance of a limited number of programs and counterparties. The company disclosed a product portfolio of 11 products, 10 of which are owned, serving government and commercial customers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm?utm_source=openai))
Key products and franchises include BioThrax, naloxone-based emergency products, and smallpox-related countermeasures, alongside contract development and manufacturing services. The CDMO arm is important because it monetizes manufacturing capacity and technical expertise beyond the proprietary product base, offering a secondary growth lever and some revenue diversification. This mix helps explain why Emergent is often viewed as both a biodefense supplier and a specialized manufacturing services provider. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm?utm_source=openai))
Geographically, Emergent remains anchored in the United States, with its headquarters in Maryland and a historically strong reliance on U.S. government demand, while also looking to expand internationally in biodefense and medical countermeasures. In its February 2026 results release, the company said it aimed to expand international penetration in its MCM biodefense business, maintain leadership in naloxone, and pursue organic and inorganic growth opportunities. That release also reported 2025 revenue of $742.9 million, net income of $52.6 million, a return to profitability, the sale of the Baltimore-Bayview facility for $36.5 million, a restarted share repurchase program, and roughly $303 million of announced medical countermeasure contract options. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1367644/000136764426000012/ebs2025-12x31exhibit99er.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
